Nachrichten zur Revolution Medicines Inc. Aktie

Revolution Medicines, Inc. 2024 Q2 - Results - Earnings Call Presentation

…

Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript

…

Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript

…

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company…

Revolution Medicines CEO sells over $182k in company stock By Investing.com

Revolution Medicines CEO sells over $182k in company stock…

Revolution Medicines, Inc. (RVMD) Q4 2023 Earnings Call Transcript

…

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company…

Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company…

Revolution Medicines, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Revolution Medicines, Inc. (RVMD) Q3 2023 Earnings Conference Call Transcript

…

Why Revolution Medicines Stock Is Crashing Today

Investors were disappointed by Revolution Medicines data, presented at ESMO.…

Why did Revolution Medicines stock go up? Encouraging data for two drugs

…

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins

Science Report on KRASG12C(ON)-Selective Inhibitors Provides Preclinical Proof-of-Principle for Companys RAS Innovation Engine and Broad Pipeline...…

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -10.84% and 4.40%, respectively, for the quarter ended June 2023.…

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress

Company to provide clinical updates for RMC-6236 at Triple (AACR-NCI-EORTC) Meeting and ESMO (European Society for Medical Oncology) Congress 2023…

Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company…

Revolution Medicines will buy EQRx in an all-stock transaction

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

EQRx Shares Rally 20% Premarket on Deal to Be Bought by Revolution Medicines

EQRx Shares Rally 20% Premarket on Deal to Be Bought by Revolution Medicines...…

Revolutin Medicines to acquire EQRx in deal that will add $1 billion in cash to its balance sheet to fund R&D

Revolution Medicines Inc. RVMD said Tuesday it has reached a definitive agreement to acquire EQRx Inc. EQRX in an all-cash…

Revolution Medicines to Buy Biopharmaceutical Company EQRx

Revolution Medicines to Buy Biopharmaceutical Company EQRx...…

Form 8-K Revolution Medicines, For: Jul 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Revolution Medicines, For: Jun 08

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company…

Revolution Medicines, Inc. (RVMD) Expected to Beat Earnings Estimates: Should You Buy?

Revolution Medicines, Inc. (RVMD) possesses the right combination of the two key ingredients for a likely earnings beat in its…

Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company…

Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company…

Insiderhandel: Vorstand verkauft Aktien von Revolution Medicines im Wert von 15.551$

Wang, Xiaolin - Vorstand - Tag der Transaktion: 2023-03-17...…

Insiderhandel: Vorstand verkauft Aktien von Revolution Medicines im Wert von 26.789$

Horn, Margaret A. - Vorstand - Tag der Transaktion: 2023-03-17...…

Insiderhandel: Chief Financial Officer verkauft Aktien von Revolution Medicines im Wert von 14.484$

Anders, Jack - Vorstand - Tag der Transaktion: 2023-03-17...…

Insiderhandel: Aufsichtsrat kauft Aktien von Revolution Medicines im Wert von 2.045.604$

Schroeder, Thilo - Aufsichtsrat - Tag der Transaktion: 2023-03-10...…

Insiderhandel: Aufsichtsrat kauft Aktien von Revolution Medicines im Wert von 12.100.000$

Schroeder, Thilo - Aufsichtsrat - Tag der Transaktion: 2023-03-07...…

Form 8-K Revolution Medicines, For: Mar 02

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Revolution Medicines prices $300M stock offering

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

REWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company…

Revolution Medicines Shares Drop 12% After Public Offering Begins

Revolution Medicines Shares Drop 12% After Public Offering Begins...…

Revolution Medicines shares slide ~7% afterhours on $300M stock offering

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Revolution Medicines Announces Commencement of Public Offering of Common Stock

REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology…

Revolution Medicines Shares Rally Premarket After RMC-6236 Update >RVMD

Revolution Medicines Shares Rally Premarket After RMC-6236 Update >RVMD...…

Revolution Medicines upgraded to overweight from neutral at J.P. Morgan

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 25% and 127.04%, respectively, for the quarter ended December 2022.…

Form 8-K Revolution Medicines, For: Feb 27

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Revolution Medicines Earnings Preview

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company…

dpa-AFX ProFeed